Ara-C affects formation of cancer cell DNA synthesome replication intermediates.

abstract：PURPOSE:Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen....

journal_title：Cancer chemotherapy and pharmacology

authors： Losa R,Fra J,López-Pousa A,Sierra M,Goitia A,Uña E,Nadal R,Del Muro JG,Gión M,Maurel J,Escudero P,Esteban E,Buesa JM

更新日期：2007-02-01 00:00:00

abstract：PURPOSE:Evasion to new treatments of advanced melanoma is still associated with a poor prognosis. Choosing the best combination of agents that can bypass resistance mechanisms remains a challenge. Sphaeropsidin A (Sph A) is a fungal bioactive secondary metabolite previously shown to force melanoma cells to undergo apop...

journal_title：Cancer chemotherapy and pharmacology

authors： Ingels A,Dinhof C,Garg AD,Maddau L,Masi M,Evidente A,Berger W,Dejaegher B,Mathieu V

更新日期：2017-05-01 00:00:00

abstract：:The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin (BCG) for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 29 patients aged a median of 70 years between January of 1991 and May of 1993. The patients received intravesical instillation of...

journal_title：Cancer chemotherapy and pharmacology

authors： Uekado Y,Hirano A,Shinka T,Ohkawa T

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Chang Z,Liu Z

更新日期：2019-04-01 00:00:00

abstract：PURPOSE:Multi-drug resistance and cumulative cardiotoxicity are major limitations for the clinical use of anthracyclines. Here, we evaluated and compared the cross-resistance of amrubicin, a third-generation synthetic anthracycline and potent topoisomerase (topo)-II inhibitor with little or no observed cardiotoxicity t...

journal_title：Cancer chemotherapy and pharmacology

authors： Mamidipudi V,Shi T,Brady H,Surapaneni S,Chopra R,Aukerman SL,Heise C,Sung V

更新日期：2012-04-01 00:00:00

abstract：:Anthracyclines are powerful cytotoxic agents, used as first-line treatment of leukemias and many other tumors, but host-tissue toxicity is their main dose-limiting factor. However, their therapeutic effects depend not only on the toxicity, hence on the dose, but also on drug resistance. Among the mechanisms that can a...

journal_title：Cancer chemotherapy and pharmacology

authors： Michelutti A,Stocchi R,Candoni A,Tiribelli M,Calistri E,Russo D,Fanin R,Damiani D

更新日期：2006-04-01 00:00:00

abstract：:MKT-077 (1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4- oxothiazolidin-2-ylidenemethyl] pyridinium chloride), a novel rhodacyanine dye in phase I/II clinical trials, may provide a new approach to cancer therapy based on the accumulation in the mitochondria of the cells of certain carcinomas, for example, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tatsuta N,Suzuki N,Mochizuki T,Koya K,Kawakami M,Shishido T,Motoji N,Kuroiwa H,Shigematsu A,Chen LB

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Stress conditions, such as glucose starvation and hypoxia, that induce glucose-regulated proteins (GRPs) in cells, are seen in most solid tumors. These conditions have been shown to cause cellular resistance to multiple anticancer drugs, such as etoposide, doxorubicin, and camptothecin. We examined the effect o...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada M,Tomida A,Yun J,Cai B,Yoshikawa H,Taketani Y,Tsuruo T

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

更新日期：2017-12-01 00:00:00

abstract：:Use of cross-sectional imaging to identify whole-body lean soft-tissue mass has recently emerged as an attractive prognostic factor for chemotherapy toxicities. Beyond that, there is increasing interest in use of lean soft-tissue mass as a more accurate method for dosing chemotherapy, as compared to body surface area....

journal_title：Cancer chemotherapy and pharmacology

authors： Hopkins JJ,Sawyer MB

更新日期：2018-07-01 00:00:00

abstract：:The effects of BCNU, CCNU, methyl-CCNU, streptozotocin, and chlorozotocin on calmodulin activity were studied in vitro and in vivo. Preincubation of BCNU, CCNU, and methyl-CCNU with calmodulin produced a concentration-dependent inhibition of in vitro calmodulin activity expressed as stimulation of cyclic nucleotide ph...

journal_title：Cancer chemotherapy and pharmacology

authors： Harrison SD Jr,Mann DM,Giles RC Jr

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-kappaB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with advanced solid malignancies. PATIENTS-METHODS:Initially, patients received MM...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu Y,Kolesar JM,Schaaf LJ,Drengler R,Duan W,Otterson G,Shapiro C,Kuhn J,Villalona-Calero MA

更新日期：2009-05-01 00:00:00

abstract：:The value of estrogen receptor (ER) status in the prediction of tumor response to combination chemotherapy was retrospectively analyzed in breast cancer patients selected for prospective controlled trials of chemotherapy (85 with advanced disease and 256 with operable tumors). All patients were previously untreated wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bonadonna G,Valagussa P,Tancini G,Di Fronzo G

更新日期：1980-01-01 00:00:00

abstract：:Dose fractionation is known to reduce the toxicity of ifosfamide and also results in an increased production of alkylating metabolites. Administration by slow infusion using the convenience of ambulatory pumps is therefore of interest. We used HPLC to investigate the stability of ifosfamide in aqueous solution (either...

journal_title：Cancer chemotherapy and pharmacology

authors： Radford JA,Margison JM,Swindell R,Lind MJ,Wilkinson PM,Thatcher N

更新日期：1990-01-01 00:00:00

abstract：:NQO1 is a reductive enzyme that is important for the activation of many bioreductive agents and is a target for an enzyme-directed approach to cancer therapy. It can be selectively induced in many tumor types by a number of compounds including dimethyl fumarate and sulforaphane. Mitomycin C is a bioreductive agent tha...

journal_title：Cancer chemotherapy and pharmacology

authors： Digby T,Leith MK,Thliveris JA,Begleiter A

更新日期：2005-09-01 00:00:00

abstract：:The chemotherapeutic effects of all-trans-retinoic acid (atRA) are mediated by the retinoic acid receptor beta (RARbeta), but RARbeta expression is reduced in a number of head and neck carcinoma (HNSCC) cells which causes resistance to RA treatment in half the patients with HNSCC. The possible mechanism for the reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Whang YM,Choi EJ,Seo JH,Kim JS,Yoo YD,Kim YH

更新日期：2005-11-01 00:00:00

abstract：PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm. S-1 has been developed as a novel oral antineoplastic agent based on the modulation of 5-fluorouracil (5-FU) bioactivity. This study was conducted to investigate the preclinical therapeutic effect of S-1 on MPM. METHODS:We used three human MPM c...

journal_title：Cancer chemotherapy and pharmacology

authors： Van TT,Hanibuchi M,Kakiuchi S,Sato S,Kuramoto T,Goto H,Mitsuhashi A,Nishioka Y,Akiyama S,Sone S

更新日期：2011-08-01 00:00:00

abstract：:PSC-833, a non immunosuppressive analogue of cyclosporin A, is an effective modulator of the multidrug-resistant tumor phenotype. Since both PSC-833 and cyclosporin A also enhance the cytotoxicity of VP-16 against drug sensitive L1210 leukemia cells in vitro we compared these agents as modulators of VP-16 efficacy in ...

journal_title：Cancer chemotherapy and pharmacology

authors： Slater LM,Sweet P,Stupecky M,Osann K

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:The survival benefit of chemotherapy (CTx) compared with best supportive care (BSC) is unclear in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC) previously treated with fluorouracil (FU), platinum (PT), and taxane (TAX). PATIENTS AND METHODS:The data of 283 consecutive pati...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura M,Iwasa S,Tsushima T,Kato K,Yasui H,Boku N,Muto M,Muro K

更新日期：2016-12-01 00:00:00

abstract：:Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

journal_title：Cancer chemotherapy and pharmacology

authors： Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:To investigate the effect of the antihistamine ketotifen on multidrug resistance in human breast cancer cells and doxorubicin toxicity in mice. METHODS:Clonogenicity assays were used to test the effect of ketotifen on human multidrug resistant breast cancer cell lines exposed to chemotherapeutic agents. Flow c...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Y,Berger SA

更新日期：2003-05-01 00:00:00

abstract：:Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Pujol JL,Cupissol D,Gestin-Boyer C,Bres J,Serrou B,Michel FB

更新日期：1990-01-01 00:00:00

abstract：:2'-deoxycoformycin (2'-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems. A clinical pharmacology/phase I study of 2'-dCF administered as a single agent has been completed (18 patients). Dose le...

journal_title：Cancer chemotherapy and pharmacology

authors： Smyth JF,Paine RM,Jackman AL,Harrap KR,Chassin MM,Adamson RH,Johns DG

更新日期：1980-01-01 00:00:00

abstract：PURPOSE:Pemetrexed, a multi-targeted antifolate that disrupts synthesis of both purines and pyrimidines, is approved for use in malignant pleural mesothelioma and non-small cell lung cancer. Pemetrexed is currently being evaluated for anti-tumor activity in a variety of solid and central nervous system tumors. We studi...

journal_title：Cancer chemotherapy and pharmacology

authors： Stapleton SL,Reid JM,Thompson PA,Ames MM,McGovern RM,McGuffey L,Nuchtern J,Dauser R,Blaney SM

更新日期：2007-03-01 00:00:00

abstract：PURPOSE:In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of...

journal_title：Cancer chemotherapy and pharmacology

authors： Dowlati A,Levitan N,Gordon NH,Hoppel CL,Gosky DM,Remick SC,Ingalls ST,Berger SJ,Berger NA

更新日期：2001-01-01 00:00:00

abstract：:A group of folate analogs of the 10-deaza-aminopterin series, which were designed on the basis of the results of an intensive biochemical and pharmacokinetic program, have been examined in therapy experiments utilizing a group of murine tumor models. These new analogs were found to be markedly superior to methotrexate...

journal_title：Cancer chemotherapy and pharmacology

authors： Sirotnak FM,DeGraw JI,Schmid FA,Goutas LJ,Moccio DM

更新日期：1984-01-01 00:00:00

abstract：BACKGROUND:3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS:Twenty patients received one dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Chao J,Synold TW,Morgan RJ Jr,Kunos C,Longmate J,Lenz HJ,Lim D,Shibata S,Chung V,Stoller RG,Belani CP,Gandara DR,McNamara M,Gitlitz BJ,Lau DH,Ramalingam SS,Davies A,Espinoza-Delgado I,Newman EM,Yen Y

更新日期：2012-03-01 00:00:00

abstract：PURPOSE:The chimeric protein BCR-ABL, a constitutively active protein-tyrosine kinase, triggers downstream signalling proteins, such as STAT3, ultimately resulting in the survival of myeloid progenitors in BCR-ABL-positive leukemias. Here, we evaluated the effect of LLL-3, an inhibitor of STAT3 activity, on cell viabil...

journal_title：Cancer chemotherapy and pharmacology

authors： Mencalha AL,Du Rocher B,Salles D,Binato R,Abdelhay E

更新日期：2010-05-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00